Bigfoot Biomedical Assets
2023
$25M
Insulet
Medical Devices & Automated Insulin DeliveryFounded 2000- HQ today: Acton, Massachusetts, United States
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
Insulet Acquisitions
2
Major Deals Covered
$50M
Disclosed Deal Value
What are Insulet's biggest acquisitions?
Insulet's largest disclosed acquisition here is Bigfoot Biomedical Assets for $25 in 2023. This page covers 2 major deals from 2022 to 2023, each with its price where disclosed and the reason behind it.
- Major deals covered
- 2
- Largest deal
- Bigfoot Biomedical Assets ($25)
- First deal
- 2022
- Most recent
- 2023
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2023 | Undisclosed | Smart insulin pen intellectual property, algorithm patents, and automated dosing data. | |
| 2022 | Undisclosed | Advanced predictive closed-loop artificial pancreas algorithm IP. |
- What companies has Insulet bought?
- Major acquisitions by Insulet documented here include Bigfoot Biomedical Assets (2023) and Automated Glucose Control LLC (2022).
- What is Insulet's most recent acquisition?
- The most recent Insulet acquisition documented here is Bigfoot Biomedical Assets, in 2023, for $25.
Automated Glucose Control LLC
2022
$25M
Insulet's Growth & Acquisition Strategy
Under CEO Jim Hollingshead, Insulet is executing a multi-pronged growth strategy: (1) Expanding Type 2 Basal-Bolus Diabetes Penetration: With over 2.5 million US type 2 diabetes patients requiring multiple daily insulin injections, Insulet secured landmark FDA clearance expanding Omnipod 5 for type 2 diabetes, creating an immense new addressable market; (2) Accelerating International Commercial Expansion: Expanding commercial sales of Omnipod 5 across the UK, Germany, France, Italy, and Australia, converting international users from traditional pens and older pumps; (3) iOS Full Smartphone Control Rollout: Launching the native Omnipod 5 App on Apple iOS, enabling iPhone users to administer insulin boluses directly from their phones without carrying an extra controller device; and (4) Next-Generation Sensor Interoperability: Deepening integrations with next-gen continuous glucose sensors from Dexcom and Abbott to maintain customer choice.
How Insulet Makes Money
Insulet operates an attractive, recurring-revenue disposable consumable business model with high customer lifetime value: (1) Omnipod 5 & DASH Pods (~95% of revenue / ~$1.95B), monetizing boxes of single-use, 72-hour pods that users replace every three days. Patients consume approximately 10 pods per month, generating reliable, predictable subscription-like cash flows; (2) Drug Delivery Partnerships (~5% of revenue / ~$100M), partnering with biopharmaceutical companies (such as Amgen for Neulasta Onpro) to deliver subcutaneous biologics using Insulet's proprietary wearable pod technology; and (3) Pharmacy Benefit Distribution Model: Unlike traditional insulin pump makers who sell $5,000+ durable capital consoles through DME suppliers with four-year warranty contracts, Insulet distributes pods through retail and mail-order pharmacies (CVS, Walgreens, Express Scripts) with low monthly copays. This eliminates upfront patient out-of-pocket hurdles, accelerates new patient acquisition, and drives gross margins near 68%.
Insulet Acquisitions FAQ
What is Insulet's general approach to M&A and acquisitions?
Insulet pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by Insulet?
Transformative transactions in Insulet's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does Insulet successfully integrate acquired companies?
Insulet deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does Insulet divest non-core corporate assets?
Yes, Insulet periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Insulet
Core profile pages, founders and related research hubs for this company.